FierceBiotechOriginal article
{"a":[{"_":"Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms","$":{"href":"/biotech/merck-halts-ph-2-alzheimers-trial-after-neuphoria-small-molecule-underwhelms","hreflang":"en"}}]}
Phase 2negativeNegative
AI Analysis
Summary
Merck halted a Phase 2 trial of its Neuphoria Therapeutics partner's Alzheimer's disease candidate after interim analysis showed the small molecule did not meet expectations. This marks another setback for the struggling partnership.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial halted after interim analysis showed the small molecule did not meet expectations
Importance:7/10
Sentiment:
-0.85
Alzheimer's diseasePhase 2 terminationsmall moleculetrial failure
Related Companies
Read the original article
Published by FierceBiotech on July 1, 2026 2:23 PM